What stage does Atlas Venture invest at?

Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.

What is Atlas Venture's typical check size?

Atlas Venture typically writes checks of $500K – $1M.

What sectors does Atlas Venture focus on?

Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Atlas Venture located?

Atlas Venture is headquartered in Cambridge, US.

Does Atlas Venture lead rounds?

Atlas Venture typically participates in rounds rather than leading them.

Atlas Venture

Venture capitalActively deploying

Cambridge · Seed–Late Stage · 24 people tracked

Also known as ATLAS VENTURE ADVISORS, INC. · Atlas Venture Ill · ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Atlas Venture focuses on medical and biotech innovation, backing early-stage life sciences companies. The firm operates an incubator through which it launches new startups, and its portfolio companies have developed approved medicines and achieved outcomes including IPOs and M&A exits. With roughly thirty years of experience, the firm positions itself at the leading edge of medical innovation.

Invests inBiotech Deep Tech Digital Health Healthtech Medical DevicesCambridgeUnited States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Check

$500K – $1M

Cambridge, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

1993

Last 12 months

3 investments

AUM

$3.2B

VC funds

Tracked investments

Team · 24 people

from the firm's website & public directories

Bruce Booth· Partner· Wellesley, MAin 𝕏

Bruce Booth is a partner at Atlas Venture focused on the discovery and development of novel medicines and therapeutic platforms. He joined Atlas in 2005 after working as a consultant at McKinsey & Company and as an investor for Caxton Health Holdings. He holds a D.Phil. in molecular immunology from Oxford University, which he attended as a British Marshall Scholar, and a BS in biochemistry from The Pennsylvania State University.

b•••@atlasventure.comreveal

David Grayzel· Managing Director· Cambridge, Massachusetts, United Statesin

David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).

d•••@atlasventure.comreveal

Jason Rhodes· Partner· Cambridge, Massachusetts, United Statesin

Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.

j•••@atlasventure.comreveal

Jean-François Formela· Partner· Boston, Massachusetts, United Statesin

Jean-François Formela is a partner at Atlas Venture, where he focuses on novel drug discovery technologies and therapeutics. He joined the firm in 1993 to establish its U.S. life sciences practice. He holds an M.D. from Paris University School of Medicine and an M.B.A. from Columbia University.

j•••@atlasventure.comreveal

Kevin Bitterman· Partner· Cambridge, Massachusettsin 𝕏

Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.

k•••@atlasventure.comreveal

Michael Gladstone· Partner· Boston, Massachusettsin 𝕏

Michael Gladstone is a partner at Atlas Venture, which he joined in 2012, and works on forming new therapeutics companies. Before Atlas, he worked at L.E.K. Consulting on business development and corporate strategy for biopharma clients, and earlier led HIV vaccine research in the Viral Pathogenesis department at Beth Israel Deaconess Medical Center. He holds an AB in biochemical sciences from Harvard College.

m•••@atlasventure.comreveal

Peter Barrett· Partner· Massachusettsin

Peter Barrett has worked at Atlas Venture since 2002, helping create therapeutic and drug discovery platform companies. Before Atlas, he co-founded Celera Genomics, serving as executive vice president and chief business officer, and previously held senior management roles at Applera. He holds a BS in chemistry from Lowell Technological Institute (now UMass Lowell) and a PhD in analytical chemistry from Northeastern University.

p•••@atlasventure.comreveal

Sasha Saberi· Partner· Columbus, Ohioin

Sasha Saberi is Chief Revenue Officer at Junto Identity, where he leads go-to-market strategy and revenue growth for the identity and access management sector. He has experience in business development and sales leadership across the cybersecurity, SaaS, and identity management industries, working with Fortune 500 companies, government agencies, and high-growth startups. Saberi has expertise in sales planning, team leadership, and operational tools including Salesforce and project management platforms.

Timothy Wolf Starr· Managing Partner· Columbus, Ohioin 𝕏

Timothy Wolf Starr is founder and Chief Executive Officer of The Venture Atlas, a venture and leadership advisory firm that works with family offices, angel networks, and venture capital teams on investment platform development. His work encompasses capital strategy, community engagement, and network design, with a focus on aligning financial performance with social and economic impact.

Aimee Raleigh· Principal· Boston, Massachusettsin 𝕏

Aimee Raleigh is a principal at Atlas Venture, where she works with founders building companies in therapeutics and biology. Before Atlas, she was a life sciences consultant at L.E.K. Consulting, advising pharmaceutical and biotech clients on strategy for early-stage therapies, asset diligence, and commercial planning. She holds a Ph.D. in bioengineering from the University of California, San Diego, and a B.S.E. in biomedical engineering from Duke University.

a•••@atlasventure.comreveal

Jernej Godec· Principal· Cambridge, Massachusettsin 𝕏

Jernej Godec is a Principal at Atlas Venture, where he works on building therapeutics companies and supporting company creation across multiple therapeutic areas. Before Atlas, he was on the investment team at Apple Tree Partners, focused on early-stage therapeutics investments and company formation. He holds a PhD in immunology from Harvard University, where he studied T cell biology, and a BA with honors in molecular and cell biology from UC Berkeley.

j•••@atlasventure.comreveal

Maurizio Fazio· Principal· Cambridge, Massachusettsin 𝕏

Maurizio Fazio is a principal at Atlas Venture, where he works on building companies that turn scientific and technological advances into new therapeutics. He earned his PhD in biological and biomedical sciences at Harvard University, studying genetic and epigenetic drivers of melanoma progression in Leonard Zon's lab, and previously was a research fellow at Memorial Sloan Kettering Cancer Center investigating epigenetic therapies for pediatric leukemia. During graduate school he held fellowships at Vida Ventures and Flagship Pioneering and taught courses at the Harvard Summer School; he holds an MD from Vita-Salute San Raffaele University in Milan.

Phillip Samayoa· Venture Partner· Cambridge, Massachusetts, United Statesin

Phillip Samayoa is a venture partner with over 15 years of experience as a biotech investor, executive, and company builder. He most recently was chief scientific officer and chief strategy officer at Generation Bio, where he built business development, portfolio strategy, and discovery research functions and raised over $750M across financings and partnerships. He was previously a principal on the Atlas investment team, co-founded Generation Bio and Dyne Therapeutics, and earlier held roles at Merck's MRL Ventures Fund and Flagship Pioneering; he holds a Ph.D. in systems biology from UC San Diego and dual B.S. degrees from MIT.

Jodie Morrison· Venture Partner· Massachusettsin

Jodie Morrison serves as CEO and Board Member at Q32 Bio Inc., a biotechnology company. She also holds positions as a venture advisor at Atlas Venture and serves on biotechnology company boards.

Rajesh Devraj· Venture Partner· Cambridge, Massachusettsin 𝕏

Steven Robinette· Venture Partner𝕏

Julia Pian· Senior Associate· United Statesin 𝕏

Julia Pian is a senior associate at Atlas Venture, where she invests in and helps build companies developing novel therapies. Before joining the firm, she completed her pediatrics residency at Boston Children's Hospital and Boston Medical Center, and she continues to practice as a pediatric hospitalist at Boston Medical Center. She holds an AB in chemical and physical biology from Harvard College, an MD from Harvard Medical School, and an MBA from Harvard Business School.

Justin Feng· Senior Associate· Cambridge, Massachusetts, United Statesin

Justin Feng is a senior associate at Atlas Venture, where he invests in and helps build companies developing novel therapeutics. He previously was a senior associate at MRL Venture Funds (the corporate venture arm of Merck & Co.) and a senior manager on the Transactions and Early Innovation Partnering teams at Johnson & Johnson, and earlier served as a principal scientist at GRO Biosciences. He holds a BS with High Honors from UC Berkeley and a Ph.D. in biology from Harvard Medical School, completed in the lab of George Church as a National Science Foundation Graduate Fellow.

Stella Paffenholz· Senior Associate· Boston, Massachusetts, United Statesin

Stella Paffenholz is a senior associate at Atlas Venture, where she builds and invests in early-stage companies developing therapies from novel biology. She was previously a principal on the investment team at Nextech Invest, investing from Series A through public markets, and earlier held roles at McKinsey & Company, Apollo Health Ventures, and Merck KGaA. She holds a PhD from Memorial Sloan Kettering Cancer Center, where she studied genetic determinants of cancer treatment response, along with an MS from the German Cancer Research Center/University of Heidelberg and a BS from the University of Bonn.

Chelsea Johnson· Senior Associate· Boston / New England𝕏

c•••@atlasventure.comreveal

Ommer Chohan· CFO

o•••@atlasventure.comreveal

Fred Destin· Londonin 𝕏

Fred Destin is the founder of Stride.VC, an artisan seed fund based in London currently investing from its second £120 million fund. Previously, he was a General Partner at Accel and Accomplice, where he led investments in companies including Deliveroo, Pillpack, Zoopla, Integral Ad Science, and TheCurrencyCloud. His current portfolio includes Buena, Conceivable Life Sciences, and Techwolf.

Josh Powers· Associate· Boston, Massachusettsin

Samy Ramadane· Analyst· New York, New Yorkin

What they invest in

from 51 of 88 portfolio companies

Biotech ×41Healthtech ×11Medical Devices ×10Deep Tech ×6AI & Machine Learning ×5Enterprise Software ×3Digital Health ×2Hardware ×2

HQs:United States×48Azerbaijan×1

Investments · 88 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 5 2024 · 4 2023 · 1 2022 · 2 2021 · 3 2020 · 2 2019 · 4 2018 · 3 2016 · 2 2015 · 7 2014 · 135 dated

Intellia Therapeutics in 𝕏NASDAQ: NTLAAug 2015

BiotechCambridge, US

Nessan Bermingham(Executive Officer, Director)Jose Rivera(Executive Officer)Carl Gordon(Director)Jean-Francois Formela(Director)John Leonard(Executive Officer, Director)Rachel Haurwitz(Director)

Board seatJean-François Formela· per SEC Form D

KALA BIOkalarx.comNASDAQ: KALAAug 2015SEC filingmedium confidence

BiotechArlington, US

Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)

Board seatKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015

Korro Bio in 𝕏NASDAQ: KRROMay 2019

RNA-editing therapeutics company using its OPERA technology platform.

BiotechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)Jean-Francois Formela(Director)

Board seatJean-François Formela· per SEC Form D

Neuroneticsneurostar.comNASDAQ: STIMApr 2015SEC filingmedium confidence

HealthtechMalvern, US

Mark R. Bausinger(Executive Officer)Stephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)P. Sherrill Neff(Director)Wilfred Jaeger(Director)

Board seatKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015

Spero Therapeutics inNASDAQ: SPROJul 2021SEC filingmedium confidence

BiotechCambridge, US

Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Reza Halse(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D · $40M raise · filed Jul 2021

Xilio Therapeuticsxiliotx.cominNASDAQ: XLOFeb 2021SEC filingmedium confidence

Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.

BiotechHealthtechWaltham, US

Paul Clancy(Director)Daniel Curran(Director)Peter Dudek(Director)David Grayzel(Director)Nancy Hong(Director)Rachel Humphrey(Director)

Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021

Disc Medicinediscmedicine.comNASDAQ: IRON

Dyne Therapeuticsdyne-tx.comin 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Lawrence Klein, Ph.D.(Director)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)David Lubner(Director)Edward Hurwitz(Director)Dirk Kersten(Director)

Exelixisexelixis.comin 𝕏NASDAQ: EXEL

Johnson & Johnsonjnj.comin 𝕏NYSE: JNJ

Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally.

BiotechHealthtechMedical DevicesNew Brunswick, US

Kymera Therapeuticskymeratx.comin 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Q32 Bioq32bio.comin 𝕏NASDAQ: QTTB

Replimunereplimune.comin 𝕏NASDAQ: REPL

Synlogicsynlogictx.comin 𝕏OTC: SYBX

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Ed Mathers(Director)Chau Khuong(Director)Bharatt Chowrira(Executive Officer)Ankit Mahadevia(Director)Michael Sheahan(Executive Officer)Peter Barrett(Director)

Unum Therapeutics in 𝕏NASDAQ: COGT

Cogent Biosciences discovers, develops, and commercializes therapies targeting genetically defined diseases, with a focus on precision medicine and addressing underlying causes rather than symptoms.

BiotechDigital HealthMedical DevicesCambridge, US

Ben Auspitz(Director)Liam Ratcliffe(Director)Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)

BoardBruce Booth(Director)

Comanche Biopharmacomanchebiopharma.cominJan 2024✓ verified

Comanche Biopharma is a biopharmaceutical company developing evidence-based therapies for preeclampsia and other life-threatening conditions of pregnancy, with a focus on maternal and neonatal health.

BiotechFemTechHealthtechConcord, US

Arthur Levin(Director)Brendan Bulik-Sullivan(Director)Muzammil Mansuri(Director)Paul Antinori(Executive Officer)Allison August(Executive Officer)Ann Taylor(Director)

Board seatDavid Grayzel· per SEC Form D

Kinaset Therapeuticskinasettherapeutics.comin 𝕏Jul 2022✓ verified

Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.

BiotechHealthtechMedfield, US

Jamil Beg(Director of the Issuer)Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Kevin Bitterman(Director of the Issuer)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)

Board seatKevin BittermanKevin Bitterman· per SEC Form D

Remix Therapeuticsremixtx.comin 𝕏Jan 2024✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Matthew Patterson(Director)Kevin Bitterman(Director)Jeff Goater(Director)

Board seatKevin Bitterman· per SEC Form D

Antaresrxantaresrx.comin 𝕏✓ verified

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Adam Friedman(Chief Executive Officer)in

Lifordi Immunotherapeuticslifordi.com✓ verified

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtech

Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)

nChroma Bionchromabio.comin 𝕏✓ verified

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD

Aerovate Therapeutics, Inc.Aug 2020SEC filingmedium confidence

Boston, US

Board seatDavid Grayzel· per SEC Form D · $75.8M raise · filed Aug 2020

Affinia Therapeuticsaffiniatx.cominOct 2025

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Carole Faig(Director)Rami Daoud(Executive Officer)Diana Brainard(Director)Rick Modi(Executive Officer, Director)Luc Vandenberghe(Director)Elliott Sigal(Director)

Board seatDavid Grayzel· per SEC Form D

Akero Therapeutics, Inc.Dec 2018SEC filingmedium confidence

South San Francisco, US

Board seatKevin Bitterman· per SEC Form D · $45.5M raise · filed Dec 2018

Akriveia TherapeuticsJan 2018SEC filinghigh confidence

BiotechSkillman, US

Thomas Beck(Director)Benjamin Auspitz(Director)Simon Tomlinson(Executive Officer, Director)

Board seatDavid Grayzel· per SEC Form D · $22.5M raise · filed Jan 2018

Amagma, Inc.Dec 2022SEC filingmedium confidence

HealthtechWaltham, US

Amy Schulman(Director)Tillman Gerngross(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D · $10M raise · filed Dec 2022

Antares TherapeuticsMay 2025SEC filingmedium confidence

BiotechBoston, US

Andrew Fedder(Executive Officer, Director)Adam Friedman(Executive Officer, Director)Brian Piper(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D · $136.7M raise · filed May 2025

Antegrin TherapeuticsDec 2014SEC filinghigh confidence

BiotechSt. Louis, US

Charles Bolten(Director)George H. Capps, II(Executive Officer)Robert Karr(Executive Officer, Director)Michael A. Yeadon(Director)David W. Griggs(Director)Thomas P. Cirrito(Director)

Board seatPeter BarrettRajesh Devraj· per SEC Form D · $26M raise · filed Aug 2017

Caldera Therapeutics, Inc.Jan 2026SEC filingmedium confidence

BiotechCambridge, US

Michelle Doig(Director)Aaron Royston(Director)Xiaodi Su(Director)Praveen Tipirneni(Executive Officer, Director)

Board seatMichael Gladstone· per SEC Form D · $37.5M raise · filed Jan 2026

Chroma Medicine, Inc.Sep 2023SEC filingmedium confidence

Boston, US

Board seatKevin Bitterman· per SEC Form D · $135M raise · filed Sep 2023

Day One Biopharmaceuticals Holding Co LLCFeb 2021SEC filingmedium confidence

BiotechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)Michael Gladstone(Director)Derek DiRocco(Director)Julie Papanek Grant(Director)John Josey(Director)Natalie Holles(Director)

Board seatMichael Gladstone· per SEC Form D · $130M raise · filed Feb 2021

Direct Vet MarketingJul 2015SEC filingmedium confidence

HealthtechPortland, US

Edward McNamara(Director)Kevin Bitterman(Director)Yumin Choi(Director)Benjamin Shaw(Executive Officer, Director)Kerry Muse(Director)David Shaw(Director)

Board seatKevin Bitterman· per SEC Form D · $52.3M raise · filed Jul 2015

Euclises PharmaceuticalsNov 2015SEC filingmedium confidence

BiotechSt. Louis, US

Charles Bolten(Director)Rick Ryan(Director)Rajesh Devraj(Executive Officer, Director)John Talley(Director)Robert W. Karr(Executive Officer, Director)Eduardo Martinez(Director)

Board seatRajesh Devraj· per SEC Form D · $2.7M raise · filed Dec 2016

Gro BiosciencesJul 2024SEC filingmedium confidence

BiotechCambridge, US

Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)Geoffrey Smith(Director)

BoardMing Fang(Director)Bruce Beutel(Director)

Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024

IFM CinqueNov 2019SEC filingmedium confidence

BiotechBoston, US

Gary Glick(Executive Officer, Director)Shelley Chu(Director)Jean-Francois Formela(Director)John Leonard(Director)

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM ContinuaNov 2019SEC filingmedium confidence

BiotechBoston, US

Jean-Francois Formela(Director)John Leonard(Director)Gary Glick(Executive Officer, Director)Shelley Chu(Director)

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM QuattroNov 2019SEC filingmedium confidence

BiotechBoston, US

Gary Glick(Executive Officer, Director)Jean-Francois Formela(Director)John Leonard(Director)Shelley Chu(Director)

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM TherapeuticsJun 2016SEC filingmedium confidence

BiotechCambridge, US

Gary Glick(Mr. Glick is a director and the President of the Issuer.)Jean-Francois Formela(Director)

Board seatJean-François Formela· per SEC Form D · filed Jun 2016

IFM TreJul 2018SEC filingmedium confidence

BiotechBoston, US

Jean-Francois Formela(Director)Vincent Miles(Director)Gary D Glick(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D · filed Aug 2018

Ikena Oncology, Inc.Jul 2025SEC filingmedium confidence

BiotechBoston, US

Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)

Board seatJean-François Formela· per SEC Form D · $75M raise · filed Jul 2025

Morphic Holding, Inc.Jun 2016SEC filingmedium confidence

BiotechWaltham, US

Barbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)Praveen Tiprirneni(Executive Officer, Director)Timothy Springer(Director)Vikas Goyal(Director)

Board seatKevin Bitterman· per SEC Form D · $51.5M raise · filed Jul 2016

Navitor Pharmaceuticalsnavitorpharma.comDec 2015SEC filingmedium confidence

BiotechCambridge, US

Jean-Francois Formela(Director)Rick Lundberg(Executive Officer)Alan Crane(Director)David Madden(Director)Marian Nakada(Director)Brian Gallagher(Director)

Board seatKevin BittermanJean-François Formela· per SEC Form D · $20.2M raise · filed May 2020

RaNA TherapeuticsJul 2015SEC filingmedium confidence

BiotechCambridge, US

Brian Gallagher(Director)Jean- Francois Formela(Director)Joshua Resnick(Director)Robert Prentiss(Executive Officer)Daniel Lynch(Director)Ronald C. Renaud, Jr.(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D · $47.5M raise · filed May 2019

Renasant Bio in 𝕏Jul 2025SEC filingmedium confidence

BiotechBerkeley, US

Evan Caplan(Director)Natalie Holles(Director)Charlotte McKee(Director)Thomas Gustafson(Executive Officer)Anna French(Director)Emily Conley(Executive Officer, Director)

Board seatKevin Bitterman· per SEC Form D · $30M raise · filed Jul 2025

Scorpion Therapeuticsscorpiontx.comJul 2024

BiotechBoston, US

Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D

Triana Biomedicines, Inc.Dec 2025SEC filingmedium confidence

Lexington, US

Board seatDavid Grayzel· per SEC Form D · $120.1M raise · filed Dec 2025

Aavantgardebioaavantgardebio.com

Akeroakerotx.comin 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Alnylamalnylam.comin 𝕏

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

Arkuda Therapeuticsarkudatx.com

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

BE Biopharmabe.bio

Calderatxcalderatx.com

Carbon Blackcarbonblack.com

Waltham, US

Patrick Morley(Executive Officer, Director)Anthony Zingale(Director)Eric Pyenson(Executive Officer)Ronald Nordin(Director)Jeff Fagnan(Director)Paul Maeder(Director)

CloudSwitch in 𝕏

Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.

Cloud ComputingEnterprise SoftwareNew York, US

Day One Biopharmaceuticalsdayonebio.comin 𝕏

Diagonaltxdiagonaltx.comin

DisplayLinkdisplaylink.comin

DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.

Enterprise SoftwareHardwareSemiconductors

Earnestearnest.agin 𝕏

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.

AgTechBiotech

Eddy Mejia(Founder)Dr. Gabe Price(Founder)

Ethyrealbioethyrealbio.comin

F Starf-star.com

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 15

IPOs and acquisitions across the tracked portfolio

Intellia TherapeuticsNASDAQ: NTLAKALA BIONASDAQ: KALAKorro BioNASDAQ: KRRONeuroneticsNASDAQ: STIMSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLODisc MedicineNASDAQ: IRONDyne TherapeuticsNASDAQ: DYNExelixisNASDAQ: EXELJohnson & JohnsonNYSE: JNJKymera TherapeuticsNASDAQ: KYMRQ32 BioNASDAQ: QTTBReplimuneNASDAQ: REPLSynlogicOTC: SYBXUnum TherapeuticsNASDAQ: COGT

Portfolio news

latest coverage across their companies

Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com

Alnylam · investing.com · Jul 17, 2026

Intellectia

Dyne Therapeutics · intellectia.ai · Jul 1, 2026

nChroma Bio Raises $75M to Advance Epigenetic Editing for Hepatitis B and D Cure | Contagion Live

nChroma Bio · contagionlive.com · Jun 25, 2026

Remix Therapeutics secures $100M, merges with Passage - Boston Business Journal

Remix Therapeutics · bizjournals.com · Jun 25, 2026

Grapevine raises $ 4.10 Mn. in an undisclosed round

Grapevine · ipoplatform.com · Mar 17, 2026

Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy

Affinia Therapeutics · clinicaltrialsarena.com · Feb 5, 2026

Lifordi Immunotherapeutics Raises Funding; Brings Total Raised to $112M

Lifordi Immunotherapeutics · finsmes.com · Nov 19, 2025

Public market activity · per SEC filings

what is this? ⓘ

1 insider ownership filing (Forms 3/4/5)

at Q32 Bio Inc. (QTTB)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

What stage does Atlas Venture invest at?: Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.
What is Atlas Venture's typical check size?: Atlas Venture typically writes checks of $500K – $1M.
What sectors does Atlas Venture focus on?: Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Atlas Venture located?: Atlas Venture is headquartered in Cambridge, US.
Does Atlas Venture lead rounds?: Atlas Venture typically participates in rounds rather than leading them.

Co-investors · 125

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 8

SynlogicDisc MedicineQ32 BioIkena Oncology, Inc.Renasant BioIkenaoncologySionnatxTriveni

$1M – $75M

F-Prime Capital Partners

F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.

Both backed · 7

Unum Therapeutics Xilio Therapeutics Affinia Therapeutics Comanche Biopharma Generation Bio nChroma BioK36 Therapeutics

$3M – $10M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 6

Kymera TherapeuticsQ32 BioLifordi Immunotherapeutics Navitor PharmaceuticalsDiagonaltxMatchpointtx

$5M

The Column Group

The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.

Both backed · 6

Johnson & Johnson Day One Biopharmaceuticals Holding Co LLC Remix Therapeutics Thumbnail for Immune DesignThumbnail for Accent TherapeuticsThumbnail for Judo Bio

$30M

Omega Funds

Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.

Both backed · 6

Antaresrx Caldera Therapeutics, Inc.Ikena Oncology, Inc.Morphic Holding, Inc.nChroma Bio Scorpion Therapeutics

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.

Both backed · 5

Alnylam Lifordi Immunotherapeutics nChroma Bio Remix TherapeuticsBE Biopharma

$50K – $250M

Pfizer Venture Investments

Pfizer Ventures is the corporate venture arm of Pfizer that invests in life science innovation across oncology, inflammation & immunology, cardiovascular, metabolic/obesity, and vaccines, as well as platform technology companies aligned with Pfizer's strategic focus areas.

Both backed · 5

Kymera Therapeutics Synlogic Arkuda Therapeuticsvisit www.nimbustx.comvisit www.trianabio.com

$5M – $20M

Foresite Capital

Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.

Both backed · 5

Intellia TherapeuticsDisc MedicineAkero Generation Bio Remix Therapeutics

Nextech Invest

Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.

Both backed · 5

Kymera Therapeutics Scorpion TherapeuticsBE BiopharmaK36 TherapeuticsMariana Oncology

$648K – $3.2M

RA Capital

RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.

Both backed · 4

Spero Therapeutics Xilio Therapeutics Day One Biopharmaceuticals Holding Co LLC Kinaset Therapeutics

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 4

Kinaset Therapeutics Lifordi Immunotherapeutics nChroma Bio Renasant Bio

$100K – $4M

Vida Ventures

Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.

Both backed · 4

Dyne Therapeutics Antaresrx Scorpion Therapeutics Vigilneuro

▶113 more co-investors

Longwood Fund GV (Google Ventures)Canaan Partners Polaris Partners Accomplice venBio Partners Digitalis Ventures New Enterprise Associates (NEA)SR One Capital Management Third Rock Ventures Hatteras Venture Partners Andreessen Horowitz Sequoia Capital Lightspeed Venture Partners Bessemer Venture Partners First Round Capital DCVC (Data Collective)EQT Life Sciences Founders Circle Capital Forbion SV Health Investors Vivo Capital MPM Capital Ysios Capital Broadview Ventures General Catalyst Craft Ventures Accel Greylock Partners Index Ventures Redpoint Ventures Founder Collective Uncork Capital Felicis Ventures SV Angel Menlo Ventures BoxGroup CRV (Charles River Ventures)DST Global ACME Capital FirstMark Slow Ventures Hardware Club AME Cloud Ventures Innovation Endeavors Accel-KKR Kapor Capital Cota Capital Stride VC Practical Venture Capital Crosslink Capital Point Nine Capital Pareto Holdings Entrepreneur First Entree Capital General Atlantic HV Capital AlleyCorp Passion Capital Wildcat Venture Partners 83North Breakthrough Energy Ventures FELIX CAPITAL Capital Factory Walden International LocalGlobe MMC Ventures Hoxton Ventures Blue Owl Capital Playground Global Motier Ventures Highbury Holdings BIOSPRING PARTNERS 20VC IrishAngels Angel Invest GE Ventures Jigsaw VC Mangrove Capital Partners Motivate Venture Capital Episode1 Kima Ventures Sofinnova Partners Day One Ventures Johnson & Johnson Innovation – JJDC Pillar VC Allen Institute for Artificial Intelligence Incubator (AI2)AlbionVC Autotech Ventures Pivotal bioVenture Partners Haatch Peak Novartis Venture Fund Kurma Partners Signal Peak Ventures Axeleo Capital Beyond Capital Access Industries Andera Partners Advent Life Sciences Roche Venture Fund New Leaf Venture Partners Cornerstone VC Leaps by Bayer Journey Ventures JMI Equity Borealis Ventures Fortino Capital ACORN BIOVENTURES Idinvest Partners Altitude Ventures Management, Llc Nest.Bio Ventures Aditum Bio

Firms observed investing alongside Atlas Venture, from public investor directories. Shared companies are the overlap with Atlas Venture's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.

$50K – $12.7M

B Capital Group

B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

GV (Google Ventures)

GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.

$250K – $50M